"With our 17 years of experience since pioneering XLIF,
- Improved clinical outcomes with fusion rates as high as 100 percent1 and up to 90 percent reduction in blood loss;2-5
- Reduced operative time by up to 15 percent, resulting in less time under anesthesia,6 and 50 percent shorter length of stay in the hospital;7 and
- Enhanced economics with up to 20 percent improved overall case efficiency and 10 percent reduction in hospital costs.7
"As a classically trained orthopedic spine surgeon with my current practice focused on trauma and complex spine surgery, I value the flexibility to treat patients with open and less invasive techniques," said Dr.
The Company's procedural focus, paired with its clinical surgeon training program led by
NuVasive cautions you that statements included in this news release that are not a description of historical facts are forward-looking statements that involve risks, uncertainties, assumptions and other factors which, if they do not materialize or prove correct, could cause NuVasive's results to differ materially from historical results or those expressed or implied by such forward-looking statements. The potential risks and uncertainties which contribute to the uncertain nature of these statements include, among others, risks associated with acceptance of the Company's surgical products and procedures by spine surgeons, development and acceptance of new products or product enhancements, clinical and statistical verification of the benefits achieved via the use of NuVasive's products (including the iGA® platform), the Company's ability to effectually manage inventory as it continues to release new products, its ability to recruit and retain management and key personnel, and the other risks and uncertainties described in NuVasive's news releases and periodic filings with the Securities and Exchange Commission. NuVasive's public filings with the Securities and Exchange Commission are available at www.sec.gov. NuVasive assumes no obligation to update any forward-looking statement to reflect events or circumstances arising after the date on which it was made.
1Isaacs RE, Sembrano JN,
2Dakwar E, Cardona RF, Smith DA, et al. Early outcomes and safety of the minimally invasive, lateral retroperitoneal transpsoas approach for adult degenerative scoliosis. Neurosurg Focus 2010;28(3):E8.
3Lehmen JA, Gerber EJ. MIS lateral spine surgery: a systematic literature review of complications, outcomes, and economics.
4Dhall SS, Wang MY, Mummaneni PV. Clinical and radiographic comparison of mini-open transforaminal lumbar interbody fusion with open transforaminal lumbar interbody fusion in 42 patients with long-term follow-up. J Neurosurg Spine 2008;9(6):560-5.
5Whitecloud TS, Roesch WW, Ricciardi JE. Transforaminal interbody fusion versus anterior-posterior interbody fusion of the lumbar spine: a financial analysis. J Spinal Disord 2001;14(2):100-3.
6Sembrano JN, Tohmeh A, Isaacs R, et al. Two-year comparative outcomes of MIS lateral and MIS transforaminal interbody fusion in the treatment of degenerative spondylolisthesis: part I: clinical findings. Spine 2016;41(8 Suppl):S123-32.
7Lucio JC, VanConia RB, DeLuzio KJ, et al. Economics of less invasive spinal surgery: an analysis of hospital cost differences between open and minimally invasive instrumented spinal fusion procedures during the perioperative period. Risk Manag Healthc Policy 2012;5:65-74.
View original content to download multimedia:http://www.prnewswire.com/news-releases/nuvasives-less-invasive-procedural-solutions-are-clinically-proven-to-reduce-operative-time-and-improve-patient-outcomes-in-spine-surgery-301097572.html
Investor Contact: Suzanne Hatcher, NuVasive, Inc., 858-458-2240, email@example.com; Media Contact: Jessica Tieszen, NuVasive, Inc., 858-283-9021, firstname.lastname@example.org